Cotinga Pharmaceuticals Market cap
What is the Market cap of Cotinga Pharmaceuticals?
The Market cap of Cotinga Pharmaceuticals, Inc. is $605.64k
What is the definition of Market cap?
Market capitalization is the market value at a point in time of the shares outstanding of a publicly traded company, being equal to the share price at that point of time times the number of shares outstanding.
= outstanding shares * previous day’s close
As outstanding stock is bought and sold in public markets, capitalization could be used as an indicator of public opinion of a company's net worth and is a determining factor in some forms of stock valuation.
Market capitalization is used by the investment community in ranking the size of companies, as opposed to sales or total asset figures. It is also used in ranking the relative size of stock exchanges, being a measure of the sum of the market capitalizations of all companies listed on each stock exchange. In performing such rankings, the market capitalizations are calculated at some significant date, such as 30 June or 31 December.
The total capitalization of stock markets or economic regions may be compared with other economic indicators. The total market capitalization of all publicly traded companies in the world was US$51.2 trillion in January 2007 and rose as high as US$57.5 trillion in May 2008 before dropping below US$50 trillion in August 2008 and slightly above US$40 trillion in September 2008. In 2014 and 2015, global market capitalization was US$68 trillion and US$67 trillion, respectively.
Market cap of companies in the Health Care sector on TSXV compared to Cotinga Pharmaceuticals
What does Cotinga Pharmaceuticals do?
Cotinga Pharmaceuticals Inc., a clinical-stage biopharmaceutical company, develops therapies for the treatment of cancer and other unmet medical needs. The company's lead compound is COTI-2, an oral small molecule targeting p53 a tumor suppressor gene. It also develops COTI-219, an oral small molecule compound targeting the mutant forms of KRAS without inhibiting normal KRAS functions. Cotinga Pharmaceuticals Inc. has a research collaboration with St. Vincent's University Hospital to evaluate COTI-2 in combination with eribulin in patients with triple negative metastatic breast cancer. The company was formerly known as Critical Outcome Technologies Inc. and changed its name to Cotinga Pharmaceuticals Inc. in January 2018. Cotinga Pharmaceuticals Inc. is based in Toronto, Canada.
Companies with market cap similar to Cotinga Pharmaceuticals
- IR Resources has Market cap of $595.62k
- Sherpa II has Market cap of $595.97k
- Universal Office Automation has Market cap of $596.66k
- Cann-Is Capital has Market cap of $596.79k
- Catenae Innovation Plc has Market cap of $604.22k
- Foodbase has Market cap of $604.64k
- Cotinga Pharmaceuticals has Market cap of $605.64k
- Tomizone has Market cap of $606.35k
- Personas Social has Market cap of $609.14k
- Transition Opportunities Corp has Market cap of $610.04k
- Blue Rhino Capital has Market cap of $610.53k
- Gravity (India) has Market cap of $611.31k
- Pacific Silk Road Resources has Market cap of $612.75k